Impact of the use of oral corticoids in organizing pneumonia post COVID-19 (the NORCOVID clinical trial) - Vienna 2024

Treatment of non-idiopathic interstitial lung diseases: what's new?

Chair(s): Marie Vermant, Antoine Froidure

Session type: Poster session

Impact of the use of oral corticoids in organizing pneumonia post COVID-19 (the NORCOVID clinical trial)

David Espejo Castellanos

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Patient education and self-management content in fibrotic interstitial lung disease results of an international multiphase Delphi consensus process with patient involvement

Thomas Riegler

Poster

Abstract

Rituximab in Hypersensitivity Pneumonitis refractory to conventional treatment: experience from two centers

Diogo Ferreira

Poster

Abstract

Late Breaking Abstract - Survival in Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Interstitial Lung Disease

Roberto Giovanni Carbone

Poster

Abstract

Late Breaking Abstract - Role of exhaled nitric oxide in predicting checkpoint inhibitor-related pneumonia?prospective observational study

Yimei Gao

Poster

Abstract

Late Breaking Abstract - Prevalence of pulmonary embolism among ILD patients with respiratory worsening

Nimrod Orr Urtreger

Poster

Abstract

Nintedanib for patients with systemic autoimmune diseases associated pulmonary fibrosis: a real-world multicentre study.

Eirini Vasarmidi

Poster

Abstract

Follow-up of patients with interstitial progressive lung diseases treated with Nintedanib.

Daniel Enrique Vega Lizarazo

Poster

Abstract

Management of interstitial lung disease in pregnancy: a case series

John Zhu

Poster

Abstract

Clinical profile of patients with Interstitial Lung Disease (ILD) and Telomere Biology Disorder (TBD): A single-center retrospective experience

Amina Hamza

Poster

Abstract

Optimizing Cardiopulmonary Rehabilitation Duration for Long COVID Patients: An Exercise Physiology Monitoring Approach.

Janos Tamas Varga

Poster

Abstract

Changes in dyspnea and cough in real-world PPF patients treated with nintedanib the INREAL study

Michael Kreuter

Poster

Abstract

Cost-effectiveness of earlier diagnosis of interstitial lung diseases (ILDs) and treatment of its progressive form, progressive pulmonary fibrosis (PPF)

Pratik Pimple

Poster

Abstract

Impact of the use of oral corticoids in organizing pneumonia post COVID-19 (the NORCOVID clinical trial)

David Espejo Castellanos

Poster

Abstract

Multicenter real-world data of antifibrotics in non-IPF progressive pulmonary fibrosis (PPF) patients

Nesrin ?cal

Poster

Abstract

Meta-analysis of rituximab treatment of systemic sclerosis related interstitial lung disease

Robert Harrington

Poster

Abstract

Inhalation innovation: phase 2b study design of inhaled pirfenidone in the treatment of progressive pulmonary fibrosis

Martin Kolb

Poster

Abstract

Association between Functional Improvement and Structural Changes in Quantitative High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis

Gracehyun Kim

Poster

Abstract

Correlation of Early Cough with Disease Activity measured by High-resolution CT in ATLAS: a Phase 1b Study of Inhaled Pirfenidone in Idiopathic Pulmonary Fibrosis

Gracehyun Kim

Poster

Abstract

Antifibrotic treatment efficacy in progressive pulmonary fibrosis: single center experience

G?lfer Nigar Okumu?

Poster

Abstract

Late Breaking Abstract - Lost in Translation: Altered fibroblast translatome in lung fibrosis.

Harry Karmouty-quintana

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}